

Client: Example Client ABC123  
123 Test Drive  
Salt Lake City, UT 84108  
UNITED STATES

Physician: Doctor, Example

**Patient: Patient, Example**

**DOB:** 3/23/2001  
**Gender:** Male  
**Patient Identifiers:** 01234567890ABCD, 012345  
**Visit Number (FIN):** 01234567890ABCD  
**Collection Date:** 00/00/0000 00:00

**Hepatitis B Virus (HBV) Perinatal Exposure Follow-up by CIA, Panel**

ARUP test code 2014285

Hepatitis B Surface Antigen

**Positive \* (Ref Interval: Negative)**

The HBsAg screening test is strongly reactive. Therefore, confirmatory testing is not necessary but is available upon request. False positives can occur. If the result is not supported by clinical evidence, repeat testing of a new sample usually helps clarify the diagnosis.

INTERPRETIVE INFORMATION: Hepatitis B Surface Ag

This assay should not be used for blood donor screening, associated re-entry protocols, or for screening Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/P).

Hepatitis B Surface Antibody

100.00 IU/L

The anti-HBs is greater than or equal to 10 IU/L. This patient has either had an antibody response to HBV vaccination, received a transfusion, or has recovered from HBV infection. This patient should be considered immune to hepatitis B.

An anti-HBs result greater than or equal to 10 IU/L implies immunity. For post-vaccination antibody testing guidelines for the general public refer to MMWR December 23, 2005/Vol. 54(No. 16);1-23, and for healthcare workers refer to MMWR December 20, 2013/Vol. 62(No. 10);1-19.

Reference Interval: anti-HBs  
9.99 IU/L or less ..... Negative  
10.00 IU/L or greater .... Positive  
Results greater than 1,000.00 IU/L are reported as greater than 1,000.00 IU/L.

Hepatitis B Panel Interp

See Note

The result pattern of the HBsAg and anti-HBs is consistent with one of three clinical scenarios:(1) a false-positive HBsAg result in a person recently vaccinated against HBV, (2) HBV infection with passively acquired anti-HBs (transfusion with blood or FFP), or (3) early HBV infection. Depending on clinical findings, testing on a new specimen for HBsAg, anti-HBs, and anti-HBc may be useful.

**H=High, L=Low, \*=Abnormal, C=Critical**

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Hepatitis B Surface Antigen	21-083-102152	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hepatitis B Surface Antibody	21-083-102152	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Hepatitis B Panel Interp	21-083-102152	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, \*=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com  
500 Chipeta Way, Salt Lake City, UT 84108-1221  
Tracy I. George, MD, Laboratory Director

Patient: Patient, Example  
ARUP Accession: 21-083-102152  
Patient Identifiers: 01234567890ABCD, 012345  
Visit Number (FIN): 01234567890ABCD  
Page 2 of 2 | Printed: 3/24/2021 8:49:25 AM  
4848